What is Notable Labs?
Notable Labs is at the forefront of accelerating the process for determining the efficacy of drug treatments or combinations for blood cancer patients. Unlike traditional approaches that target broad patient populations, Notable Labs focuses on identifying patient groups with unmet needs. The company specializes in accurately predicting which specific drugs or drug combinations will yield high success rates within these niche segments, thereby optimizing treatment pathways and improving patient outcomes.
How much funding has Notable Labs raised?
Notable Labs has raised a total of $57.4M across 6 funding rounds:
Angel/Seed
$6M
Other Financing Round
$50K
Series A
$10M
Series B
$40M
Debt
$350K
Debt
$1M
Angel/Seed (2015): $6M with participation from First Round Capital, 11.2 Capital, Accelerate Brain Cancer Cure, Eric Kwan, Y Combinator, UpHonest Capital, and Refactor Capital
Other Financing Round (2016): $50K led by Undisclosed
Series A (2017): $10M supported by Builders VC
Series B (2019): $40M featuring Lifeforce Capital Gp I and B Capital Group
Debt (2020): $350K backed by PPP
Debt (2021): $1M with participation from PPP
Key Investors in Notable Labs
B Capital Group
B Capital is a venture capital firm that focuses on empowering entrepreneurs by investing in early and late-stage companies within the Technology, Healthcare, and Climate sectors. With over $8 billion in assets under management and a portfolio comprising more than 190 companies, B Capital aims to support founders throughout the company-building lifecycle.
First Round Capital
First Round Capital is a venture capital firm that invests in innovative startups across various sectors. The company focuses on supporting entrepreneurs and helping them achieve significant results, with a notable track record of successful IPOs and acquisitions.
Y Combinator
Established in 2005 and located in Mountain View, California, Y Combinator provides seed funding for startup businesses and to gauge investors for businesses.
What's next for Notable Labs?
The substantial enterprise-level funding and recent strategic investment signal a strong growth trajectory for Notable Labs. This capital infusion is expected to fuel further research and development, enhance its predictive modeling capabilities, and potentially expand its clinical partnerships. The company's focus on unmet needs within blood cancer patient groups positions it for significant impact and market leadership in precision oncology.
See full Notable Labs company page
